Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status
- 468 Downloads
Follicular variant of papillary thyroid carcinoma (FVPTC) is currently treated like conventional papillary thyroid carcinoma (cPTC). Recent reports indicate that encapsulated FVPTC behaves like follicular adenomas, while infiltrative FVPTC behaves like cPTC. This raises the possibility that histology and/or mutation status might help personalize management of FVPTC regarding extent of surgery, intensity of follow-up, and targeted therapy. This study correlates histological features, immunoreactivity for CK19, HBME, and Gal, and BRAF V600E mutation with lymph node (LN) metastasis and follow-up in FVPTC.
Forty-eight FVPTC (21 with regional lymph node metastasis [LN+] and 27 with negative lymph nodes [LN−]) were reviewed. Demographics, tumor focality, size, circumscription, follicular architecture, lymphovascular invasion, extrathyroidal extension (ETE), and margin status were charted. Macrodissected formalin-fixed paraffin-embedded sections from 47 (21 LN+ and 26 LN−) cases were analyzed for BRAF V600E (1799T>A) mutation using real-time PCR. Correlations between the variables and LN status were calculated.
Sixty-two percent of cases with ETE demonstrated LN metastasis, while 59 % of cases with circumscribed tumors were LN−. In multivariable analysis, ETE and tumor size ≥1 cm were the best predictors of LN+ status, whereas in cases without ETE, the infiltrative pattern and tumor size provided the “best fit.” Immunostains and BRAF mutation status were not helpful. All four tumors that recurred were LN+, with infiltrative borders, and lacked the BRAF mutation.
Tumor circumscription, extrathyroidal extension, and tumor size ≥ 1.0 cm are predictors of lymph node status in FVPTC.
KeywordsFollicular variant Papillary thyroid carcinoma BRAF V600E mutation Extrathyroidal extension Circumscription Histological features
Conflict of interest
The authors have no conflicts of interest to disclose.
- Barroeta JE, Baloch ZW, Lal P, Pasha TL, Zhang PJ, LiVolsi VA (2006) Diagnostic value of differential expression of CK19, galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Endocr Pathol 17:225–234CrossRefPubMedGoogle Scholar
- DeLellis RA, Williams ED (2004) Tumours of the thyroid and parathyroid. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) Pathology and genetics of tumours of endocrine organs. World Health Organization classification of tumors. IARC Press, LyonGoogle Scholar
- Hazard JB, Crile CJ, Dinemore RS, Hawk WA, Kenyon R (1955) Neoplasms of the thyroid. Classification, morphology, and treatment. Arch Pathol Lab Med 59:502–513Google Scholar
- Lee SR, Jung CK, Kim TE, Bae JS, Jung SL, Choi YJ, Kang CS (2013) Molecular genotyping of follicular variant papillary thyroid carcinoma correlates with diagnostic category of fine-needle aspiration cytology: values of RAS mutation testing. Thyroid 23:1416–1422PubMedCentralCrossRefPubMedGoogle Scholar
- Lindsay S (1964) Pathology of the thyroid gland. In: Pitt-Rivers R, Trotter WR (eds) The thyroid gland, vol 2, 1st edn. Butterworths, Washington, DC, pp 223–270Google Scholar
- Lindsay S (1960) Carcinoma of the thyroid gland. A clinical and pathologic study of 293 patients at the University of California Hospital. Charles C. Thomas, SpringfieldGoogle Scholar
- Rivera M, Ricarte-Filho J, Knauf J, Shaha A, Tuttle M, Fagin JA, Ghossein RA (2010) Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol 23:1191–1200CrossRefPubMedGoogle Scholar